Showing 3181-3190 of 10546 results for "".
DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.Increased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisWhat’s New in Rosacea Treatments?
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39737/James Q. Del Rosso, DO, FAOCD, reviews the latest therapeutic innovations and evidence in rosacea management. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privAI for Patient Education and More
https://practicaldermatology.com/series/c-suite-chats/ai-for-patient-education-and-more/36239/Anastasia Georgievskaya, founder of Haut.AI, discusses the impact of new artificial intelligence tools such as a virtual skincare try-on that shows customers how sunscreen and its ingredients will impact skin over time.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Maui Derm Panel: GLP-1 Agonists Can Help Psoriasis Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/maui-derm-panel-glp-1-agonists-can-help-psoriasis-patients/32917/Only 11% of Maui Derm 2025 audience members polled said they were comfortable prescribing weight-loss drugs, and 49% said they were not at all—but they should be, according to the presenters of “Psoriasis Update 2025” at the conference in Maui, Hawaii.DermwireTV 2024 Year in Review
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisChronic Hand Eczema
https://practicaldermatology.com/series/updates-atopic-dermatitis/chronic-hand-eczema/29146/Dr. Raj Chovatiya, Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research, talks about chronic hand eczema.